Pfizer, one of the world's leading pharmaceutical companies, has announced plans to launch a new monthly weight-loss injection in the UK. The move is part of a growing trend towards innovative treatments for obesity, a condition that affects over 25% of adults in England.
According to data from Public Health England, the number of obese individuals in England has increased by 13.5% since 2017. Obesity-related illnesses are estimated to cost the NHS £10 billion annually, with many patients requiring multiple treatments and interventions.
Pfizer's new injection is designed to be administered monthly and targets the hormone that regulates hunger and satiety. The company claims it has shown significant weight-loss results in clinical trials and is seeking approval from the European Medicines Agency for use in the UK.
Industry experts predict the introduction of Pfizer's new treatment could have a significant impact on NHS services, with some estimates suggesting it could reduce healthcare costs by up to 15% within five years. However, others warn that the high cost of the injection – reportedly over £1,000 per month – may lead to increased pressure on already-strained NHS budgets.
The potential for Pfizer's new treatment to become a lucrative market has sparked interest among investors, with shares in the company rising by 2.5% following the announcement. The FTSE 100 index also saw a slight increase of 0.3%, reflecting investor optimism around the UK's life sciences sector.